Cogstate Limited (ASX:CGS): Clinical Trial Contracts and Earnings Shape the Business Outlook

Aditi Sarkar

28 October 2026 03:07 PM AEDT

Cogstate Limited (ASX:CGS): Clinical Trial Contracts and Earnings Shape the Business Outlook

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

FY26 revenue reached US$60.9 million, while EBITDA was US$18.3 million.
Net Clinical Trials sales contracts totalled US$89.0 million for FY26.
Contracted future revenue stood at US$118.5 million at the FY26 reporting date.
September-quarter FY27 sales contracts reached US$25.1 million.
Contract timing, margins and automation investment remain relevant operational factors.

Cogstate Limited (ASX:CGS) develops digital cognitive assessments and provides specialist services that support the collection and quality of clinical trial data. Its clinical trials activities serve pharmaceutical and biotechnology sponsors conducting studies of neurological and psychiatric conditions. The company’s FY26 financial results and October 2026 business update provide a picture of contract demand, reported earnings and the timing of future revenue recognition.

FY26 Revenue and Earnings

For the financial year ended 30 June 2026, Cogstate Limited (ASX:CGS) reported revenue of US$60.9 million, an increase of 15%. Clinical Trials contributed US$58.4 million, while Healthcare contributed US$2.5 million. The relative size of these segments demonstrates that clinical research services account for most reported revenue.

EBITDA was US$18.3 million, equivalent to a 30% margin, and EBIT reached US$15.2 million. Profit before tax was US$16.1 million, with net profit after tax of US$11.9 million. Gross margin decreased to 58% from 61%, while operating expenses were US$17.0 million. These measures show that revenue growth and margin movement need to be considered together rather than treated as interchangeable indicators.

Operating cash inflow was US$8.5 million, below reported EBITDA. At 30 June 2026, Cogstate Limited (ASX:CGS) held US$34.8 million in cash and reported no debt. Differences between earnings and cash generation are relevant because the timing of customer payments and project delivery can influence working capital.

Contract Awards and the Latest Quarterly Update

Net Clinical Trials contracts signed in FY26 amounted to US$89.0 million, compared with US$41.3 million in FY25, an increase of 116%. Contracted future revenue reached US$118.5 million, with US$48.3 million expected to be recognised during FY27 as of the August results release. The schedule remains dependent on the progression of individual studies.

In its 12 October 2026 update, Cogstate Limited (ASX:CGS) reported US$25.1 million of net sales contracts for the September 2026 quarter, compared with US$21.42 million in the corresponding quarter. The company identified five Phase 3 trials in bipolar disorder or depression across two customers as accounting for more than 80% of the quarter’s contract value. This concentration illustrates how a limited number of trial awards can materially shape quarterly bookings.

Cogstate also reported 171 active trials at 30 June 2026, compared with 110 at 1 July 2025. The volume of studies provides operational context, although it does not establish when contracted work will become recognised revenue.

Automation, Cash Flow and Delivery Considerations

Cogstate Limited (ASX:CGS) has introduced AI-enabled capabilities in rater training and central monitoring and outlined an automation development programme across FY27 and FY28. Management indicated that much of this expenditure would be capitalised. The programme adds a technology investment component to the company’s existing scientific and service delivery model.

Clinical trials can be delayed, changed or cancelled by sponsors. Consequently, the contracted revenue balance is not equivalent to cash already received or revenue already earned. Customer concentration within quarterly awards, lower FY26 gross margin and the gap between EBITDA and operating cash flow are additional factors in assessing the reported results. Management described FY27 revenue as sensitive to contract execution and conversion timing rather than issuing a fixed numerical revenue forecast.

Key Insights

The FY26 results show a business principally supported by clinical trial services, with higher reported revenue and a larger contracted work pipeline. The September 2026 quarter added further sales contracts, including a concentrated group of psychiatric trials. For Cogstate Limited (ASX:CGS), the distinction between new contract awards, scheduled recognition and operating cash receipts remains central to interpreting subsequent financial reporting.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.